Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension

Matthew R. Weir, John Josselson, Mark J. Giard, J. Bryan Warren, Jeffrey N. Posner, Yui-wing F Lam, Darwin E. Zaske, Elijah Saunders

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The daily administration of 240 to 360 mg of diltiazem lowered blood pressure in a dose-related pattern similar to that seen in patients taking a daily dosage of 50 to 100 mg of atenolol. Sustained-release diltiazem was administered twice daily and atenolol once. Goal blood pressure was defined as <90 mm Hg or a reduction of ≥10 mm Hg for patients with baseline pressures of 95 to 99 mm Hg in the supine position and was achieved in 60% of diltiazem-treated and 63% of atenolol-treated patients. The mean diltiazem dosage at the end of the study was 329 mg daily; for atenolol it was 80 mg daily. Adverse reactions considered possibly or probably drug related were reported by 26% of diltiazem patients and 38% of atenolol patients. Although both drugs were associated with a slower heart rate, atenolol patients showed a significantly greater negative chronotropic effect. Diltiazem, in a sustained-release form taken twice daily, is as effective as atenolol as a sole antihypertensive agent. It has a favorable side-effect profile and may be a useful alternative antihypertensive medication compared with existing β-blocker therapy with atenolol.

Original languageEnglish (US)
Pages (from-to)36-41
Number of pages6
JournalThe American Journal of Cardiology
Volume60
Issue number17
DOIs
StatePublished - Dec 14 1987
Externally publishedYes

Fingerprint

Atenolol
Diltiazem
Hypertension
Antihypertensive Agents
Blood Pressure
Supine Position
Pharmaceutical Preparations
Heart Rate
Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. / Weir, Matthew R.; Josselson, John; Giard, Mark J.; Warren, J. Bryan; Posner, Jeffrey N.; Lam, Yui-wing F; Zaske, Darwin E.; Saunders, Elijah.

In: The American Journal of Cardiology, Vol. 60, No. 17, 14.12.1987, p. 36-41.

Research output: Contribution to journalArticle

Weir, Matthew R. ; Josselson, John ; Giard, Mark J. ; Warren, J. Bryan ; Posner, Jeffrey N. ; Lam, Yui-wing F ; Zaske, Darwin E. ; Saunders, Elijah. / Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. In: The American Journal of Cardiology. 1987 ; Vol. 60, No. 17. pp. 36-41.
@article{c3453c7b939b4cdb909913df55c25df4,
title = "Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension",
abstract = "The daily administration of 240 to 360 mg of diltiazem lowered blood pressure in a dose-related pattern similar to that seen in patients taking a daily dosage of 50 to 100 mg of atenolol. Sustained-release diltiazem was administered twice daily and atenolol once. Goal blood pressure was defined as <90 mm Hg or a reduction of ≥10 mm Hg for patients with baseline pressures of 95 to 99 mm Hg in the supine position and was achieved in 60{\%} of diltiazem-treated and 63{\%} of atenolol-treated patients. The mean diltiazem dosage at the end of the study was 329 mg daily; for atenolol it was 80 mg daily. Adverse reactions considered possibly or probably drug related were reported by 26{\%} of diltiazem patients and 38{\%} of atenolol patients. Although both drugs were associated with a slower heart rate, atenolol patients showed a significantly greater negative chronotropic effect. Diltiazem, in a sustained-release form taken twice daily, is as effective as atenolol as a sole antihypertensive agent. It has a favorable side-effect profile and may be a useful alternative antihypertensive medication compared with existing β-blocker therapy with atenolol.",
author = "Weir, {Matthew R.} and John Josselson and Giard, {Mark J.} and Warren, {J. Bryan} and Posner, {Jeffrey N.} and Lam, {Yui-wing F} and Zaske, {Darwin E.} and Elijah Saunders",
year = "1987",
month = "12",
day = "14",
doi = "10.1016/0002-9149(87)90457-7",
language = "English (US)",
volume = "60",
pages = "36--41",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "17",

}

TY - JOUR

T1 - Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension

AU - Weir, Matthew R.

AU - Josselson, John

AU - Giard, Mark J.

AU - Warren, J. Bryan

AU - Posner, Jeffrey N.

AU - Lam, Yui-wing F

AU - Zaske, Darwin E.

AU - Saunders, Elijah

PY - 1987/12/14

Y1 - 1987/12/14

N2 - The daily administration of 240 to 360 mg of diltiazem lowered blood pressure in a dose-related pattern similar to that seen in patients taking a daily dosage of 50 to 100 mg of atenolol. Sustained-release diltiazem was administered twice daily and atenolol once. Goal blood pressure was defined as <90 mm Hg or a reduction of ≥10 mm Hg for patients with baseline pressures of 95 to 99 mm Hg in the supine position and was achieved in 60% of diltiazem-treated and 63% of atenolol-treated patients. The mean diltiazem dosage at the end of the study was 329 mg daily; for atenolol it was 80 mg daily. Adverse reactions considered possibly or probably drug related were reported by 26% of diltiazem patients and 38% of atenolol patients. Although both drugs were associated with a slower heart rate, atenolol patients showed a significantly greater negative chronotropic effect. Diltiazem, in a sustained-release form taken twice daily, is as effective as atenolol as a sole antihypertensive agent. It has a favorable side-effect profile and may be a useful alternative antihypertensive medication compared with existing β-blocker therapy with atenolol.

AB - The daily administration of 240 to 360 mg of diltiazem lowered blood pressure in a dose-related pattern similar to that seen in patients taking a daily dosage of 50 to 100 mg of atenolol. Sustained-release diltiazem was administered twice daily and atenolol once. Goal blood pressure was defined as <90 mm Hg or a reduction of ≥10 mm Hg for patients with baseline pressures of 95 to 99 mm Hg in the supine position and was achieved in 60% of diltiazem-treated and 63% of atenolol-treated patients. The mean diltiazem dosage at the end of the study was 329 mg daily; for atenolol it was 80 mg daily. Adverse reactions considered possibly or probably drug related were reported by 26% of diltiazem patients and 38% of atenolol patients. Although both drugs were associated with a slower heart rate, atenolol patients showed a significantly greater negative chronotropic effect. Diltiazem, in a sustained-release form taken twice daily, is as effective as atenolol as a sole antihypertensive agent. It has a favorable side-effect profile and may be a useful alternative antihypertensive medication compared with existing β-blocker therapy with atenolol.

UR - http://www.scopus.com/inward/record.url?scp=0023653649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023653649&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(87)90457-7

DO - 10.1016/0002-9149(87)90457-7

M3 - Article

C2 - 3318375

AN - SCOPUS:0023653649

VL - 60

SP - 36

EP - 41

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 17

ER -